Literature DB >> 23187732

Ubiquitin- and ubiquitin-like proteins-conjugating enzymes (E2s) in breast cancer.

Ioannis A Voutsadakis1.   

Abstract

Breast cancer is the most common malignancy in women and a significant cause of morbidity and mortality. Sub-types of breast cancer defined by the expression of steroid hormones and Her2/Neu oncogene have distinct prognosis and undergo different therapies. Besides differing in their phenotype, sub-types of breast cancer display various molecular lesions that participate in their pathogenesis. BRCA1 is one of the common hereditary cancer predisposition genes and encodes for an ubiquitin ligase. Ubiquitin ligases or E3 enzymes participate together with ubiquitin activating enzyme and ubiquitin conjugating enzymes in the attachment of ubiquitin (ubiquitination) in target proteins. Ubiquitination is a post-translational modification regulating multiple cell functions. It also plays important roles in carcinogenesis in general and in breast carcinogenesis in particular. Ubiquitin conjugating enzymes are a central component of the ubiquitination machinery and are often perturbed in breast cancer. This paper will discuss ubiquitin and ubiquitin-like proteins conjugating enzymes participating in breast cancer pathogenesis, their relationships with other proteins of the ubiquitination machinery and their role in phenotype of breast cancer sub-types.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23187732     DOI: 10.1007/s11033-012-2261-0

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  36 in total

1.  NEDD8 recruits E2-ubiquitin to SCF E3 ligase.

Authors:  T Kawakami; T Chiba; T Suzuki; K Iwai; K Yamanaka; N Minato; H Suzuki; N Shimbara; Y Hidaka; F Osaka; M Omata; K Tanaka
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

2.  Expression of the novel human gene, UBE2Q1, in breast tumors.

Authors:  Atefeh Seghatoleslam; Mohsen Nikseresht; Sayed Mohammad Shafiee; Ahmad Monabati; Mohammad Mehdi Namavari; Abdolrassul Talei; Akbar Safaei; Ali Akbar Owji
Journal:  Mol Biol Rep       Date:  2011-12-14       Impact factor: 2.316

3.  Evolutionary pathways in BRCA1-associated breast tumors.

Authors:  Filipe C Martins; Subhajyoti De; Vanessa Almendro; Mithat Gönen; So Yeon Park; Joanne L Blum; William Herlihy; Gabrielle Ethington; Stuart J Schnitt; Nadine Tung; Judy E Garber; Katharina Fetten; Franziska Michor; Kornelia Polyak
Journal:  Cancer Discov       Date:  2012-04-10       Impact factor: 39.397

4.  Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.

Authors:  Daniel Schramek; Andreas Leibbrandt; Verena Sigl; Lukas Kenner; John A Pospisilik; Heather J Lee; Reiko Hanada; Purna A Joshi; Antonios Aliprantis; Laurie Glimcher; Manolis Pasparakis; Rama Khokha; Christopher J Ormandy; Martin Widschwendter; Georg Schett; Josef M Penninger
Journal:  Nature       Date:  2010-09-29       Impact factor: 49.962

5.  Long-range transcriptional control of progesterone receptor gene expression.

Authors:  Jamie Bonéy-Montoya; Yvonne S Ziegler; Carol D Curtis; Jonathan A Montoya; Ann M Nardulli
Journal:  Mol Endocrinol       Date:  2009-12-01

6.  The ubiquitin-proteasome system as a molecular target in solid tumors: an update on bortezomib.

Authors:  A Milano; F Perri; F Caponigro
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

7.  Sensitization against anticancer drugs by transfection with UBE2I variant gene into ras-NIH3H3 mouse fibroblasts.

Authors:  Tooru Shiratori; Hideaki Shimada; Akiko Kagaya; Mari Kuboshima; Yoshihiro Nabeya; Toshio Machida; Ken-Ichiro Goto; Masaki Takiguchi; Takenori Ochiai; Takaki Hiwasa
Journal:  Anticancer Res       Date:  2007 Sep-Oct       Impact factor: 2.480

8.  Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2.

Authors:  Xiaobo Wang; Karine Belguise; Nathalie Kersual; Kathrin H Kirsch; Nora D Mineva; Florence Galtier; Dany Chalbos; Gail E Sonenshein
Journal:  Nat Cell Biol       Date:  2007-03-18       Impact factor: 28.824

9.  Systematic in vivo RNAi analysis identifies IAPs as NEDD8-E3 ligases.

Authors:  Meike Broemer; Tencho Tenev; Kristoffer T G Rigbolt; Sophie Hempel; Blagoy Blagoev; John Silke; Mark Ditzel; Pascal Meier
Journal:  Mol Cell       Date:  2010-12-10       Impact factor: 17.970

10.  Proteasome inhibition represses ERalpha gene expression in ER+ cells: a new link between proteasome activity and estrogen signaling in breast cancer.

Authors:  G L Powers; S J Ellison-Zelski; A J Casa; A V Lee; E T Alarid
Journal:  Oncogene       Date:  2009-11-30       Impact factor: 9.867

View more
  13 in total

Review 1.  Regulation and role of post-translational modifications of enhancer of zeste homologue 2 in cancer development.

Authors:  Haiqi Lu; Guangliang Li; Chenyi Zhou; Wei Jin; Xiaoling Qian; Zhuo Wang; Hongming Pan; Hongchuan Jin; Xian Wang
Journal:  Am J Cancer Res       Date:  2016-12-01       Impact factor: 6.166

Review 2.  Ubiquitination involved enzymes and cancer.

Authors:  Mei-juan Zhou; Fang-zhi Chen; Han-chun Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

3.  Induction of cell proliferation, clonogenicity and cell accumulation in S phase as a consequence of human UBE2Q1 overexpression.

Authors:  Mohammad Ali Fahmidehkar; Sayed Mohammad Shafiee; Ebrahim Eftekhar; Laleh Mahbudi; Atefeh Seghatoleslam
Journal:  Oncol Lett       Date:  2016-07-13       Impact factor: 2.967

4.  E2 superfamily of ubiquitin-conjugating enzymes: constitutively active or activated through phosphorylation in the catalytic cleft.

Authors:  Ilaria Valimberti; Matteo Tiberti; Matteo Lambrughi; Boris Sarcevic; Elena Papaleo
Journal:  Sci Rep       Date:  2015-10-14       Impact factor: 4.379

Review 5.  Roles of ubiquitination and SUMOylation on prostate cancer: mechanisms and clinical implications.

Authors:  Zhenbang Chen; Wenfu Lu
Journal:  Int J Mol Sci       Date:  2015-02-27       Impact factor: 5.923

Review 6.  Mechanism and disease association of E2-conjugating enzymes: lessons from UBE2T and UBE2L3.

Authors:  Arno F Alpi; Viduth Chaugule; Helen Walden
Journal:  Biochem J       Date:  2016-10-15       Impact factor: 3.857

7.  Digital gene expression profiling analysis and its application in the identification of genes associated with improved response to neoadjuvant chemotherapy in breast cancer.

Authors:  Xiaozhen Liu; Gan Jin; Jiacheng Qian; Hongjian Yang; Hongchao Tang; Xuli Meng; Yongfeng Li
Journal:  World J Surg Oncol       Date:  2018-04-23       Impact factor: 2.754

8.  UBE2T promotes proliferation via G2/M checkpoint in hepatocellular carcinoma.

Authors:  Li-Li Liu; Ji-Min Zhu; Xiang-Nan Yu; Hai-Rong Zhu; Xuan Shi; Enkhnaran Bilegsaikhan; Hong-Ying Guo; Jian Wu; Xi-Zhong Shen
Journal:  Cancer Manag Res       Date:  2019-09-13       Impact factor: 3.989

Review 9.  The Molecular Basis of Ubiquitin-Conjugating Enzymes (E2s) as a Potential Target for Cancer Therapy.

Authors:  Xiaodi Du; Hongyu Song; Nengxing Shen; Ruiqi Hua; Guangyou Yang
Journal:  Int J Mol Sci       Date:  2021-03-26       Impact factor: 5.923

10.  Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer.

Authors:  Longyang Jin; Qiang Cai; Shouhua Wang; Shuqing Wang; Tanmoy Mondal; Jiandong Wang; Zhiwei Quan
Journal:  Cell Death Dis       Date:  2018-10-03       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.